Results 71 to 80 of about 111,529 (192)

A case report of the cascade filtration system: A safe and effective method for low-density lipoprotein apheresis during pregnancy

, 2008
PubMedID: 18937724Women with familial hypercholesterolemia (FH) should be treated effectively during pregnancy, as elevated low-density lipoprotein cholesterol (LDL-C) levels may result in life-threatening consequences.
Haydardedeoglu B., Guvenc B., Tekinturhan F., Ertorer M.E.   +3 more
core   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

World apheresis registry report

, 2007
The establishment of national apheresis registries has been helpful to learn about therapeutic profiles and adverse event incidences. During 2003, the World Apheresis Registry was established and centers from all countries were invited to participate to ...
Stegmayr, Bernd,, Ptak, Jan,, Wikström, Björn,, Ptak, Jan, Stegmayr, Bernd   +4 more
core   +1 more source

Low-density lipoprotein apheresis shows a rapid response to proteinuria due to C3 glomerulonephritis: a case report and literature review

Renal Replacement Therapy
Background C3 glomerulonephritis (C3GN) is a rare renal disorder caused by dysregulation of the alternative complement pathway, resulting in abnormal C3 activation and deposition.
Hideki Matsumura, Yuko Fujii, Tomoko Tanaka, Maki Kagitani, Akira Ashida   +4 more
doaj   +1 more source

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia

Journal of Lipid Research, 1997
Apheresis only partially controls raised low density lipoprotein cholesterol levels in patients with homozygous familial hypercholesterolemia, who usually respond poorly to lipid-lowering drugs.
A D Marais, R P Naoumova, J C Firth, C Penny, C K Neuwirth, G R Thompson   +5 more
doaj   +1 more source

Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia

, 2012
[[abstract]]"Uremic patients with hyperlipidemia are classified at high atherogenic risk due to oxidative stress induced by regular hemodialysis process (hemoincompatibility) and a high level of oxidized low-density lipoprotein (ox-LDL).
;Chen, Tung-Sheng;Liou, Show-Yih;Wu, Hsi-Chin;Tsai, Fuu-Jen;Tsai, Chang-Hai;黃志揚;HUANG, CHIH-YANG;Chang, Yen-Lin
core  

Reduction of hepatitis C virus load by H.E.L.P.–LDL apheresis

, 2001
Background The association of HCV with apolipoprotein B containing lipoproteins has been observed and this led to the assumption that the LDL receptor may also serve as a candidate receptor for HCV.
R. W. Grunewald, Ramadori, Giuliano, Mueller, Gerhard A., G. A. Müller, M. Monazahian, Grunewald, Rolf W., E. Wieland, G. Ramadori, R. Thomssen, Schettler, Volker, Wieland, Eberhard, Thomssen, R., V. Schettler, Monazahian, M.   +13 more
core   +1 more source

La LDL-aferesi:stato attuale. LDL-apheresis: current status

, 2001
PURPOSE: State of the art of LDL-apheresis and treatment of severe familiar hypercholesterolemia. PATIENTS AND METHODS: Clinical experience of treatment with LDL-apheresis of pediatric and adult patients with familial hypercholesterolemia using the ...
Di Giacomo S., STEFANUTTI, Claudia, Lucani G, Vivenzio A   +3 more
core  

The 2009 2nd Italian Consensus Conference on LDL-apheresis

, 2010
The '2009 2nd Italian Consensus Conference on LDL-apheresis' was held in Rome, Italy, 15 May 2009. The latest scientific evidence and the information processed in more than two decades of LDL-apheresis application require new guidelines.
STEFANUTTI, Claudia, C. Stefanutti
core   +1 more source

Impact of LDL-Apheresis on inflammation and microcirculation

Atherosclerosis Supplements, 2009
Lipid-apheresis (LIPID-A) is highly effective in reduction of pro-atherosclerotic LDL-cholesterol and lipoprotein (a). It has been demonstrated in prospective and retrospective analyses to reduce major cardiovascular events. In addition to improvement of pro-atherosclerotic lipoprotein milieu, LIPID-A exerts pleiotropic effects on inflammation and ...
Koziolek, Michael J., Mueller, Gerhard A.   +1 more
openaire   +3 more sources